You’re basically running three arguments at once: (1) consent, (2) technical risk (off-targets / irreversible heritable change), and (3) slippery slope to enhancement. I’ll push back using the same structure, but also anchor it in what the data actually shows right now—not just theory.
First, the “no consent from the embryo” point sounds strong, but it isn’t unique to CRISPR. Every reproductive decision is made without consent from the future person—IVF selection, choosing a partner, even basic prenatal screening. We already accept that society allows parents to make irreversible biological decisions for future children when the intent is to prevent serious harm. The ethical line people usually draw isn’t “consent vs no consent,” it’s “therapeutic prevention vs enhancement.”
Second, on off-target mutations: this was a major concern in early CRISPR work, but it’s not where the frontier is anymore. High-fidelity Cas9 variants and improved guide RNA design have reduced detectable off-target editing to extremely low levels in many experimental systems—often below the limit of standard sequencing detection in optimized contexts. That doesn’t mean “zero risk,” but it does mean the claim “we are scrambling genomes unpredictably” is no longer an accurate description of the state of the technology.
A useful comparison is somatic CRISPR therapy, not embryos: in clinical trials for sickle cell disease and beta-thalassemia, CRISPR-edited cells have produced functional cures or near-cures in the majority of treated patients (many trials reporting >80–90% elimination of severe symptoms after treatment). That matters because it shows the editing machinery can be precise enough to produce stable, life-altering benefits without widespread genomic chaos.
Third, the “heritable irreversibility” argument is real—but it cuts both ways. Germline editing would indeed propagate changes, which is why no responsible regulatory framework currently allows clinical embryo editing in most countries. But it also means the risk has to be weighed against preventing a mutation that would otherwise propagate suffering through entire family lines indefinitely. For some monogenic diseases (like Huntington’s or Tay-Sachs), the “status quo” is not neutral—it is a guaranteed transmission probability in affected lineages.
On preimplantation genetic testing (PGT/PGD), which already exists: in IVF, it can identify embryos without known disease-causing variants with high accuracy (often reported around ~95%+ for detecting known single-gene mutations, depending on the lab and condition). That already allows many at-risk couples to avoid passing on severe diseases without gene editing. So even the strongest pro-CRISPR argument isn’t “we need this immediately,” but rather “there are edge cases where selection fails or produces no viable embryos, and editing could expand options.”
Finally, the “slippery slope to designer babies” concern is more about governance than biology. We already regulate stronger technologies with similar dual-use risks (nuclear tech, IVF, opioids, etc.) without banning the underlying science. The existence of a possible misuse pathway isn’t itself evidence that therapeutic use must be rejected—only that strict boundaries matter.
So the core counter is this: the risks you’re pointing to are either (a) already substantially reduced compared to early CRISPR fears, (b) already partially addressed by existing reproductive technologies like PGT, or (c) real but governance-dependent rather than inherent to the idea of germline therapy itself.
The strongest version of your argument isn’t “this is too dangerous to ever work,” but “this should be restricted until safety, equity, and regulation are far more mature.” That’s a much harder position to dismiss—and it actually matches where most of the real-world policy debate already is.
06:55 AM